Product Information
LEVETIRACETAM 250 MG TABLET is a generic product labeled by Novadoz Pharmaceuticals LLC, priced at $0.0562 per EA under NDC 72205009492. Its NADAC has been published 159 times since Jun 7, 2023.
FDA first approved this application on Oct 7, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Novadoz Pharmaceuticals LLCNDC
72205009492
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVETIRACETAMApproval Type
Generic (ANDA)
FDA Application
ANDA214815FDA Approved
10/7/2022
TE Code
AB
On Market Since
10/7/2022
Pharmacological Classes
Price Statistics
The NADAC for LEVETIRACETAM 250 MG TABLET has been published 159 times since Jun 7, 2023, and over the history we have for it it has declined 14.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0562 per EA |
|---|---|
| All-time high | $0.0691 (Jul 12, 2023) |
| All-time low | $0.0454 (Nov 20, 2024) |
| 52-week high | $0.0605 |
| 52-week low | $0.0562 |
| Median price | $0.0600 |
| Average price | $0.0599 |
| Largest weekly change | +30.7% (Aug 21, 2024) |
| Weeks tracked | 159 |
| Tracking since | Jun 7, 2023 |
Generic Alternatives
The matcher finds 16 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 12% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novadoz Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levetiracetam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVETIRACETAM 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LEVETIRACETAM 250 MG TABLET, manufactured by Novadoz Pharmaceuticals LLC, is $0.0562 per EA (NDC 72205009492), effective Sep 30, 2026.
How has the price of LEVETIRACETAM 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for LEVETIRACETAM 250 MG TABLET has declined 14.2%. It has been tracked across 159 weekly CMS publications since Jun 7, 2023.
What are the highest and lowest recorded NADAC prices for LEVETIRACETAM 250 MG TABLET?
Since Jun 7, 2023, the NADAC for LEVETIRACETAM 250 MG TABLET has ranged from a low of $0.0454 (Nov 20, 2024) to a high of $0.0691 (Jul 12, 2023), with a median of $0.0600 per EA.
Are there cheaper alternatives to LEVETIRACETAM 250 MG TABLET?
Yes. 16 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LEVETIRACETAM 250 MG TABLET, is $0.0494 per EA — about 12% below LEVETIRACETAM 250 MG TABLET.
Who manufactures LEVETIRACETAM 250 MG TABLET?
LEVETIRACETAM 250 MG TABLET (NDC 72205009492) is labeled by Novadoz Pharmaceuticals LLC, and CMS classifies it as a generic product.